文章核心观点 - 公司获得2250万美元ART100系统采购订单，标志商业重大转折点，有望推动全球业务拓展 [1][3] 订单详情 - 公司获2250万美元ART100系统采购订单，采购方为美国境外一家有政府和医疗客户资源的公司 [1] - 按订单条款，2250万美元将在2025年全额支付，双方已启动入职、物流规划和部署调度并立即实施 [2] 订单意义 - 此订单是公司重要商业里程碑，标志全面进入创收阶段，且只是公司全球目标市场一小部分 [3] - 订单表明公司商业模式广泛激活，体现市场对技术的信心和需求，为全球部署奠定基础 [4] 公司发展 - 公司正与多地区医疗公司和政府机构进行高级谈判，有望近期达成商业协议，支持商业扩张战略 [4] - 此前公司有成功临床整合和制造扩张等里程碑，正扩大商业基础设施以支持全球业务 [5] 公司概况 - 公司是商业阶段医疗设备公司，专注呼吸支持和血液监测解决方案，有FDA批准产品和增长的IP组合 [6]

文章核心观点 - 公司FDA获批的ART100系统的采用开始对商业化产生积极影响，是关键里程碑并助力商业验证 [1] 公司情况 - 公司是商业阶段医疗设备公司，专注先进呼吸支持和实时血液监测解决方案 [5] - 公司的INSPIRA ART100系统获美国FDA批准，用于美国体外循环和美国以外ECMO程序，是INSPIRA ART500下一代系统的技术基础 [5] - 公司正在推进HYLA™专有血液传感器平台，可连续无创监测 [5] - 公司有多款获批产品、不断增长的知识产权组合并对运营进行战略精简，在生命支持和医疗科技领域地位渐显 [5] ART100系统应用情况 - 过去几个月，ART100系统已成功集成到美国顶级一级医院的临床工作流程中 [2] - 具体医院部署细节保密，但涉及美国一级设施 [2] 商业影响 - ART100系统的持续使用引发美国和国际医疗机构及政府部门的关注 [3] - 公司正与多地区利益相关方进行商业讨论，并扩大运营能力以支持ART100预期采用 [3] - 临床应用向全球市场传递积极信号，表明公司技术受医生信任、融入工作流程并推动商业需求 [4] 未来展望 - 公司预计近期宣布更多战略部署和商业里程碑 [4]

RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with whic ...

RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with which the Company is currently in advanced- ...

Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizationsRA'ANANA, Israel, May 29, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic shift to accelerate the commercialization of its U.S. FDA (Food ...

RA'ANANA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira” or the “Company”), a pioneering company in advanced respiratory support and diagnostic systems, today announced an evolution in its executive structure that reflects recent internal assessments and long-term strategic alignment efforts. Mr. Joe Hayon, Co-Founder and President of Inspira, will be stepping down from his operational role as President of Inspira, and will continue to serve as an ac ...

RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures.  As part of this advancement, Inspira will deploy the ...

文章核心观点 - 公司从部署于美国领先医疗设施的FDA批准生命支持技术获得初始收入，标志着其在美国医疗市场部署战略取得重大成就，未来将继续扩大临床覆盖范围并推进生命支持系统的采用 [1][2][3] 公司业务进展 - 公司收到美国经销商Glo - Med Networks Inc.为交付FDA批准的INSPIRA™ ART100系统支付的款项，收入在几十万美金的低端范围，该系统已安装在美国一家顶级学术医疗中心，还计划在另一家领先学术医疗中心安装 [1][2] - 公司首席执行官表示首笔收入是公司在美国医疗领域立足的变革性里程碑，成功系统安装验证了创新技术和与顶级医疗机构合作的能力，公司期待扩大临床覆盖范围并推进生命支持系统在美国领先医疗设施中的采用 [3] 公司技术与产品 - INSPIRA ART100系统获FDA批准用于体外循环手术，为公司旗舰产品INSPIRA™ ART500系统的基础技术，ART500系统旨在为呼吸衰竭患者提供无机械通气的直接血液氧合，目标是革新190亿美元的机械通气市场 [3] - 公司的HYLA血液传感器技术旨在提供无需抽血的连续实时血液监测，包括INSPIRA ART500、HYLA血液传感器和一次性患者套件在内的管线产品正在开发中，尚未获得监管批准 [4] 公司合作方 - Glo - Med Networks Inc.以提供独特医疗解决方案著称，与全球顶级医疗设备和生物医学公司合作，通过长期合作关系和姊妹公司Med - Stat Consulting Services, Inc.广泛接触全球下一代医疗产品，客户包括纽约和佛罗里达的大型知名医疗组织，在多个地区设有办事处和合作伙伴公司 [5]

RA'ANANA, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the successful completion of the first human treatment using its U.S. Food and Drug Administration-cleared INSPIRA™ ART100 system in a critical life-support procedure. The procedure was successfully performed by expert physicians at Westchester Medical Center in New York State, marking ...

Inspira's innovative FDA-cleared INSPIRA™ ART100 system was successfully deployed at premier U.S. hospital, with systems in place for clinical use RA'ANANA, Israel, March 25, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has successfully completed the installation, training program and operational readiness for its INSPIRA ART100 system for cardiopulmonary bypa ...